NEURO CONGRESS Market Analysis and Reports | Italy Conference Series

Market Analysis - NEURO CONGRESS 2024

 Market Analysis

Delve Insight’s Neuro Congress 2024- Market Insights, Epidemiology, and Market Forecasts - 2032 Report presents Neuro Congress in the US, EU5 (Germany, France, Italy), Historical and Projected It provides an in-depth understanding of the epidemiology, and market trends of Vascular Dementia. , Spain, UK) and Japan.

The Neuro Congress Market Report provides current treatment practices, new agents, market shares for each therapy, and current and projected 7MM Neuro Congress market size from 2019 to 2032 . Market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs are analyzed to curate the best opportunities and assess market potential.

Region covered

  • USA
  • EU5 (Germany, France, Italy, Spain, UK)
  • Japan

Study Period: 2019–2032 

Market Disease Understanding and Treatment Algorithms

In Neurology Conference, these symptoms occur when the brain is damaged due to problems with its blood supply. Neuro Congress 2024is an etiologic category of dementia characterized by severe cognitive impairment resulting from ischemic or hemorrhagic stroke or hypo perfusion affecting brain regions important for memory, cognition, and behavior. Neuro Congress is a decline in thinking ability caused by conditions in which blood flow to various areas of the brain is blocked or reduced, resulting in a lack of oxygen and nutrients. Cognitive and brain function can be greatly influenced by the size, location and number of vascular changes.


More and more experts prefer the term vascular cognitive impairment (VCI) to vascular dementia. This is because we believe it better expresses the concept that changes in vascular thinking can range from mild to severe. According to the guidelines of the Neuro Congress 2024Classification Consensus Study (VICCCS), Neuro Congress he can be divided into four main subtypes. Subcortical ischemic Neuro Congress 2024(SIVAD); multiple (cortical) dementia; and mixed dementia.

Neuro Congress 2024is caused by a variety of conditions that block the blood flow and oxygen supply to the brain and damages the blood vessels in the brain.

Diagnosis of  Neurology
A diagnosis of Neuro Congress 2024should be considered in patients with significant vascular risk factors, stroke, or cardiac disease presenting with acute changes in cognition. Brain imaging showing the presence of relevant lesions of cerebrovascular disease is essential for the diagnosis of vascular dementia.

Neurology Treatment
In Neuro Congress, decreased blood flow damages brain tissue. Blood flow to brain tissue can be reduced by a partial blockage or completely blocked by a blood clot. There is currently no cure for this condition or way to reverse the damage already done. . However, treatment can prevent further damage to the brain and slow progression in people with vascular dementia
As our understanding of vascular cognitive impairment (VCI) and Neuro Congress 2024has improved, promising symptomatic and preventive therapies have been developed. Primary prevention treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors. This can be achieved by addressing vascular risk factors such as arterial hypertension, dyslipidemia, atrial fibrillation, myocardial infarction, coronary artery disease, diabetes, atherosclerosis, smoking and hyper homocysteinemia.
Secondary prevention includes treatment of stroke and prevention of acute stroke through early detection and appropriate treatment. prevent stroke recurrence; slow the progression of brain changes associated with Neuro Congress 2024through intensive management of pre-existing risk factors;
Treatment goals include symptom improvement of core symptoms such as cognition, function and behavior. slowing disease progression; treating neuropsychiatric symptoms such as depression and anxiety.

Epidemiology of Neuro Congress
The epidemiology of the disease covered in the report includes the overall prevalence of Neurology cases, the diagnosed prevalence of dementia cases, and the diagnosed prevalence of vascular dementia. We provide historical and projected epidemiology segmented by prevalence cases, and age-specific diagnosed prevalence cases of Neurology. Dementia in Neuro Congress 2024Scenario 7MM covers the US, EU5 (Germany, France, Italy, Spain, UK) and Japan from 2019 to 2032.
Japan, making him the second most common among 7MM. These cases are expected to grow to 2032 at a CAGR of 3.37% over the forecast period (2022-2032).

Key Findings
Delve Insight estimates the overall prevalence of dementia cases in 7 million people in 2021 to be 21,591,565, increasing at a compound annual growth rate (CAGR) of 2.42% during the study period It is expected that The prevalence of dementia diagnosed in
7MM will be identified at 11,344,408 in 2021, expected to increase at a he CAGR of 3.60% during the 2019-2032 study period.
Delve Insight estimates that 2,795,390 out of 7 million people will be diagnosed with Neuro Congress 2024in 2021, increasing at his CAGR of 3.60%. Among
7MM, the United States will have the most diagnosed cases of Neuro Congress 2024in 2021 with 1,110,606 cases, accounting for 40% of all diagnosed prevalent cases in 7MM.
Neuro Congress 2024is prevalent in the 60+ age group but appears to be rare below this age group. We therefore stratified the diagnosed prevalence cases into age groups of 60–70, 71–80, 81–90, and ≥91 years.
In 2021, EU-5 will account for 893,124 prevalence diagnosed cases of vascular dementia, increasing at a CAGR of 3.26% to 2032.
In 2021, 791,660 cases of Neuro Congress 2024will be diagnosed in Japan, making him the second most common among 7MM. These cases are expected to grow to 2032 at a CAGR of 3.37% over the forecast period (2022-2032).

Neuro Congress 2024Epidemiology by Country
The Epidemiology segment also provides epidemiological data and results for Neuro Congress 2024in the US, EU5 (Germany, France, Italy, Spain, UK) and Japan.

The Neuro Congress 2024Market Insights Report presents current and projected Neuro Congress 2024market size by treatment, epidemiology, emerging therapies, market share for each therapy, 2019-2032 Neuro Congress 2024market size. It provides an in-depth understanding of the 7 million (US, EU5 (US) UK, Italy, Spain, France, Germany) and Japan)

Some of the salient features of the Neuro Congress 2024 Market Report:

  • 7 Million Neuro Congress 2024market size is estimated at USD 2.23 billion in 2021, growing by 4.05 over the study period (2019-2021)
  • It is projected to grow at a CAGR of 50%. -2032) grow. Neuro Congress 2024major pharmaceutical companies such as Charsire Biotechnology Corp, ProNeurogen, Cyclerion Therapeutics, Pfizer, Acadia Pharmaceuticals, Resverlogix Corp, Pinteon Therapeutics, and Aribio are expected to significantly transform the Neuro Congress 2024market.
  • New therapies for Neuro Congress 2024expected to enter the market during the forecast period include BAC (CSTC1, also known as CHARSIRE Trauma Complex 1), PNA1, Apabetalon, CY6463, AR1001, PNA5 and others.
  • The United States has the highest percentage of people with vascular dementia. Japan, on the other hand, consistently boasts her second-highest number of cases among the seven million countries. Among the EU5 countries, Germany has the highest number of people with vascular dementia.
  • The overall market for Neuro Congress 2024is expected to increase due to the increasing prevalence of cases worldwide and the consequent increase in treatment options. In addition to these, the expected launch of new therapies will boost the market for Neuro Congress 2024treatment during the forecast period.

 Market Dynamics

The Neuro Congress 2024market is expected to experience significant growth in the future as companies show interest in developing therapeutic agents. Rise in the number of population groups at high risk of vascular dementia, such as the elderly and smokers, and better understanding of diagnostic modalities will boost the Neuro Congress 2024market in the coming years. In addition, increasing focus on developing Neuro Congress 2024treatments for underlying disease and lack of FDA-approved agents are important growth considerations for the Neuro Congress 2024market. In addition to these, the anticipated introduction of new treatments will have a significant impact on the Neuro Congress 2024treatment market during the forecast period.

On the other hand, factors such as clinical challenges in disease treatment, patients unaware of early symptoms of vascular dementia, underdiagnosis of the disease, and lack of knowledge about the etiology of the disease hinder the opportunities of the Neuro Congress 2024market. 

Market Report Scope

  • Study Period: 2019-32
  • Coverage: 7 Million [US, EU5 (Germany, France, Italy, Spain, UK) and Japan]
  • Leading Neuro Congress 2024Company: Charsire Biotechnology Corp, ProNeurogen, Cyclerion Therapeutics, Pfizer, Acadia Pharmaceuticals, Resverlogix Corp, Pinteon Therapeutics, Aribio, etc.
  • Major Neuro Congress 2024pipeline therapeutics: BAC (CSTC1, also known as CHARSIRE Trauma Complex 1), PNA1, Apabetalone, CY6463 , AR1001
  • Vascular Therapeutic Evaluation of Dementia: Current and Emerging Therapies for Vascular Dementi
  • Neuro Congress 2024Market Dynamics: Market Drivers and Barriers in Vascular Dementia
  • Competitive Intelligence Analysis: SWOT Analysis, PESTLE Analysis, Porter's Five Forces, BCG Matrix, Market Entry Strategies
  • Unmet Needs
  • KOL Opinions
  • Analyst Opinions
  • Neuro Congress 2024Market Access and Reimbursement Ocular Dementia

Neuro Congress Pipeline
DelveInsight's Neuro Congress 2024Pipeline Insights, 2022 report provides comprehensive insight into the status of the Neuro Congress 2024pipeline. Covers pipeline drug profile with clinical and preclinical stage products and leading Neuro Congress 2024companies including Charsire Biotechnology Corp, ProNeurogen, Cyclerion Therapeutics, Pfizer, Acadia Pharmaceuticals, Resverlogix Corp, Pinteon Therapeutics and Ariboo I'm here.

Epidemiology of Neuro congress
DelveInsight's Neuro Congress 2024Epidemiology Projections to 2032 report provides an in-depth understanding of the disease, historical and projected epidemiology of Neuro Congress 2024in 7MM. H. US, EU5 (Germany, Spain, Italy, France). , UK) and Japan.

Alzheimer's Disease (AD) Pipeline
DelveInsight's Alzheimer's Disease (AD) Pipeline Insights, 2022 report provides comprehensive insight into over 100 companies and 100 pipeline drugs in the Alzheimer's disease pipeline landscape . This includes clinical-stage and preclinical-stage products and major Alzheimer's drugs such as Eisai, Biogen, Changchun Huayang High-Tech Co., Ltd., Hoffmann-La Roche, vTv Therapeutics, AZ Therapy, Seresin, Neurotrope, Lindra. Includes drug profiles for pipelines that include pharmaceutical companies. and many others.

Alzheimer's disease Market
 Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2030 report covers Alzheimer's disease, historical and predictive epidemiology, Alzheimer's disease market trends, market drivers and barriers, and major Alzheimer's disease companies (AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and many others,

Epilepsy Market
DelveInsight's Epilepsy - Market Insights, Epidemiology and Market Forecast - 2030 report includes Neurelis, Biocodex, Aquestive Therapeutics, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Eisai Pharmaceuticals, Janssen Pharmaceuticals, Eisai, Zogenix, UCB. , SK Life Sciences, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Supernus Pharmaceuticals, Lundbeck, Pfizer, and many others.

Key Findings

  • It is predicted that Neuro Congress 2024prevalence is likely to grow in the coming years as the anticipated launch of promising therapeutics, supported by an increasing diagnosed population, is likely to lead to an increase in market size.
  • Neuro Congress 2024market size across seven major markets to grow at a compound annual growth rate (CAGR) of 4.05% over the study period (2019-2032) from USD 2.23 billion in 2021.
  • Future therapies like BAC could bring about a significant positive change in the market size of vascular dementia.
    US have the largest market for Neuro Congress 2024compared to EU-5 (Germany, France, Italy, Spain, UK) and Japan.
  • Among the EU-5 countries, Germany had the largest market size throughout the study period (2019-2032) and Spain had the smallest market size for vascular dementia.
  • Among 7MMs, the United States will have the highest number of diagnosed cases of VaD in 2021 with 1,110,606 cases, accounting for 40% of all diagnosed prevalent cases in 7MMs.
  • Neuro Congress 2024(VaD) is prevalent in the 60+ age group but appears to be rare below this age group. We therefore stratified the diagnosed prevalence cases into age groups of 60–70, 71–80, 81–90, and ≥91 years.
  • In 2021, EU-5 will account for 893,124 prevalence-diagnosed cases of VaD, increasing at a CAGR of 3.26% to 2032.
  • In 2021, 791,660 cases of VaD will be diagnosed in Japan, making him the second most common among 7MM. These cases are expected to increase by 2032 at a CAGR of 3.37% over the forecast period (2022-2032).

The Neuro Congress 2024Market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into

  • Prevalent Cases of Dementia
  • Diagnosed Prevalent Cases of Dementia
  • Diagnosed Prevalent Cases of Vascular Dementia
  • Age-specific Diagnosed Prevalent Cases of Vascular Dementia

The current pipeline for Neuro Congress 2024 consists of a small number of products in early, mid- and late-stage clinical development. The lack of approved treatments, especially for vascular dementia, is a serious unmet need. As a result, it became necessary to develop a new unit. Furthermore, due to the rapidly increasing patient population, further research on the clinical efficacy of pharmacological treatments for Neuro Congress 2024is urgently needed. To address this urgent need, leading Neuro Congress 2024companies are developing new drugs in clinical trials for diseases such as Alzheimer's disease and vascular dementia. PNA1, a rationally designed angiotensin (1-7) Mas receptor agonist, is being developed by ProNeurogen, a neuroinflammatory company, for the treatment of vascular dementia. Resverlogix's Apabetalon is a novel epigenetic therapeutic that is taken orally to improve the condition of people with vascular disease by down-regulating the expression of disease-associated genes.

On behalf of the Organizing Committee, we are delighted to invite you to “37th European Neurology Congress 2024 which will be held on June 13-14, 2024 in Rome Italy”
We organize conferences by offering a platform to all academicians, researchers and industry professionals. Conference will be scheduled on wide range of topics and it will be helpful for scientific fraternity to be connected while staying at their preferred place. "The conference's goal is to discuss the difficulties in comprehending, identifying, and treating a variety of neurological illnesses.